TRVI
Trevi Therapeutics, Inc.
$17.93
+0.32 (+1.82%)
At close · Jul 2
Market Cap
$2.55B
Shares
141,979,708
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$17.93
Open$17.73
Day$17.51–18.25
52W$5.53–19.26
Avg vol 30d1.9M
Short int14.4M · 10.1% float · 14.8d
Short vol56%
Last earningsMay 5, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 5
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Strong Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+46% above
+
Price vs 50-day avg
+20% above
◦
RSI (14)
66 · neutral
+
MACD trend
positive
+
52-week position
90% · near high
Sentiment · smart money
Bearish
◦
Trend (MA cross)
50d $15 › 200d $12 — 50d above 200d
−
Institutional flow
3 of 200 funds reported for Jun 30 · net -214 sh shares · +1 new
◦
Insider flow
No net insider activity over 90 days
−
Short interest
10.11% of float · ▲ +5.7% MoM · 14.8 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
200 holders — near 3-yr high, broad support
Fundamentals
Strong
+
EPS growth
+32% Y/Y
−
Free cash flow
$-42.1M
+
Balance sheet
net cash $18.9M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Jul 26, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+46% above
Bullish
Price vs 50-day avg
+20% above
Bullish
RSI (14)
66 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
90% · near high
Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $15 › 200d $12 — 50d above 200d
Institutional flow
Distributing
3 of 200 funds reported for Jun 30 · net -214 sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.11% of float · ▲ +5.7% MoM · 14.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
200 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $6
Now $18 · 90%
52-wk high $19
vs 200-day avg +46%
vs 50-day avg +20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TRVI
this stock
Trevi Therapeutics, Inc.
|
$2.55B | +43.2% | — | — | 10.1% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TRVI | -0.4% | +33.3% | +60.0% | -3.9% | +43.2% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -1.8% | +34.6% | +51.9% | -3.6% | +34.0% |